Top
Summary
All studies
Mortality
Serious outcomes
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
All pacritinib studies
 
Feedback
Home
c19early.org COVID-19 treatment researchPacritinibPacritinib (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Outcomes in COVID-19 pacritinib studies

0 0.5 1 1.5+ All studies -28% 1 200 Improvement, Studies, Patients Relative Risk Mortality -28% 1 200 RCTs -28% 1 200 Late -28% 1 200 Pacritinib for COVID-19 c19early.org October 2024 Favorspacritinib Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cafardi (DB RCT) -28% 1.28 [0.53-3.10] death 10/99 8/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Late treatment -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk All studies -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk 1 pacritinib COVID-19 study c19early.org October 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Effect extraction pre-specified(most serious outcome) Favors pacritinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cafardi (DB RCT) -28% 1.28 [0.53-3.10] 10/99 8/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Late treatment -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk All studies -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk 1 pacritinib COVID-19 mortality result c19early.org October 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Favors pacritinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cafardi (DB RCT) -28% 1.28 [0.53-3.10] death 10/99 8/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Late treatment -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk All studies -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk 1 pacritinib COVID-19 serious outcome c19early.org October 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Effect extraction pre-specified(most serious outcome) Favors pacritinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cafardi (DB RCT) -28% 1.28 [0.53-3.10] death 10/99 8/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Late treatment -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk All studies -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk 1 pacritinib COVID-19 Randomized Controlled Trials c19early.org October 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Effect extraction pre-specified(most serious outcome) Favors pacritinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cafardi (DB RCT) -28% 1.28 [0.53-3.10] 10/99 8/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Late treatment -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk All studies -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk 1 pacritinib COVID-19 RCT mortality result c19early.org October 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Favors pacritinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cafardi (DB RCT) -28% 1.28 [0.53-3.10] death 10/99 8/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Late treatment -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk All studies -28% 1.28 [0.53-3.10] 10/99 8/101 28% higher risk 1 pacritinib COVID-19 peer reviewed studies c19early.org October 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.6 Effect extraction pre-specified(most serious outcome) Favors pacritinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cafardi (DB RCT) -28% 1.28 [0.53-3.10] death 10/99 8/101 Improvement, RR [CI] Treatment Control Cafardi (DB RCT) -28% 1.28 [0.35-4.61] death 5/99 4/101 Cafardi (DB RCT) 25% 0.75 [0.43-1.32] progression 17/99 23/101 Cafardi (DB RCT) -6% 1.06 [0.66-1.70] progression 26/99 25/101 Cafardi (DB RCT) -17% 1.17 [0.76-1.81] no improv. 31/99 27/101 Pacritinib COVID-19 outcomes c19early.org October 2024 Favors pacritinib Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit